OBJECTIVE: To assess the cost effectiveness of primary angioplasty, compared with medical management with thrombolytic drugs, to achieve reperfusion after acute myocardial infarction (AMI) from the perspective of the UK NHS. DESIGN: Bayesian evidence synthesis and decision analytic model. METHODS: A systematic review was conducted and Bayesian statistical methods used to synthesise evidence from 22 randomised control trials. Resource utilisation was based on UK registry data, published literature and national databases, with unit costs taken from routine NHS sources and published literature. MAIN OUTCOME MEASURE: Costs from a health service perspective and outcomes measured as quality-adjusted life years (QALYs). RESULTS: For the base case, the incremental cost-effectiveness ratio of primary angioplasty was 9241 pounds sterling for each additional QALY, with a probability of being cost effective of 0.90 for a cost-effectiveness threshold of 20,000 pounds sterling. Results were sensitive to variations in the additional time required to initiate treatment with primary angioplasty. CONCLUSIONS: Primary angioplasty is cost effective for the treatment of AMI on the basis of threshold cost-effectiveness values used in the NHS and subject to a delay of up to about 80 minutes. These findings are mainly explained by the superior mortality benefit and the prevention of non-fatal outcomes associated with primary angioplasty for delays of up to this length.
OBJECTIVE: To assess the cost effectiveness of primary angioplasty, compared with medical management with thrombolytic drugs, to achieve reperfusion after acute myocardial infarction (AMI) from the perspective of the UK NHS. DESIGN: Bayesian evidence synthesis and decision analytic model. METHODS: A systematic review was conducted and Bayesian statistical methods used to synthesise evidence from 22 randomised control trials. Resource utilisation was based on UK registry data, published literature and national databases, with unit costs taken from routine NHS sources and published literature. MAIN OUTCOME MEASURE: Costs from a health service perspective and outcomes measured as quality-adjusted life years (QALYs). RESULTS: For the base case, the incremental cost-effectiveness ratio of primary angioplasty was 9241 pounds sterling for each additional QALY, with a probability of being cost effective of 0.90 for a cost-effectiveness threshold of 20,000 pounds sterling. Results were sensitive to variations in the additional time required to initiate treatment with primary angioplasty. CONCLUSIONS: Primary angioplasty is cost effective for the treatment of AMI on the basis of threshold cost-effectiveness values used in the NHS and subject to a delay of up to about 80 minutes. These findings are mainly explained by the superior mortality benefit and the prevention of non-fatal outcomes associated with primary angioplasty for delays of up to this length.
Authors: T A Lieu; R J Gurley; R J Lundstrom; G T Ray; B H Fireman; M C Weinstein; W W Parmley Journal: J Am Coll Cardiol Date: 1997-12 Impact factor: 24.094
Authors: D Hartwell; J Colquitt; E Loveman; A J Clegg; H Brodin; N Waugh; P Royle; P Davidson; L Vale; L MacKenzie Journal: Health Technol Assess Date: 2005-05 Impact factor: 4.014
Authors: Brahmajee K Nallamothu; Eric R Bates; Jeph Herrin; Yongfei Wang; Elizabeth H Bradley; Harlan M Krumholz Journal: Circulation Date: 2005-02-07 Impact factor: 29.690
Authors: A E Ades; Mark Sculpher; Alex Sutton; Keith Abrams; Nicola Cooper; Nicky Welton; Guobing Lu Journal: Pharmacoeconomics Date: 2006 Impact factor: 4.981
Authors: Christian Asseburg; Yolanda Bravo Vergel; Stephen Palmer; Elisabeth Fenwick; Mark de Belder; Keith R Abrams; Mark Sculpher Journal: Heart Date: 2007-02-03 Impact factor: 5.994
Authors: Richard A Brogan; Christopher J Malkin; Phillip D Batin; Alexander D Simms; James M McLenachan; Christopher P Gale Journal: World J Cardiol Date: 2014-08-26
Authors: John P Greenwood; Neil Maredia; Aleksandra Radjenovic; Julia M Brown; Jane Nixon; Amanda J Farrin; Catherine Dickinson; John F Younger; John P Ridgway; Mark Sculpher; Stephen G Ball; Sven Plein Journal: Trials Date: 2009-07-29 Impact factor: 2.279
Authors: Ander Regueiro; Julia Bosch; Victoria Martín-Yuste; Alba Rosas; Maria Teresa Faixedas; Joan Antoni Gómez-Hospital; Jaume Figueras; Antoni Curós; Angel Cequier; Javier Goicolea; Antonio Fernández-Ortiz; Carlos Macaya; Ricard Tresserras; Laura Pellisé; Manel Sabaté Journal: BMJ Open Date: 2015-12-09 Impact factor: 2.692